Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telcyta (TLK286) vs. Iressa (gefitinib) in non-small cell lung cancer
NCT00080340Phase 3Completed
- Sponsor
- Telik, Inc.
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 8
01
Overview
A Phase 3 trial of canfosfamide in non-small cell lung cancer (NSCLC), sponsored by Telik, Inc.. Status: completed.
02
Drugs
canfosfamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00080340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080340.